Sebra / Shutterstock.com
The US District Court for the Southern District of Florida ruled yesterday that Apotex did not infringe Amgen patents centring on its biologic drug Neulasta (pegfilgrastim).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Apotex, Amgen, Neulasta, notice of commercial marketing, FDA, patent, biosimilar